Brief: Adagene Achieves Key Milestone In Collaboration With Exelixis For SAFEbody® Novel Masked Antibody-Drug Conjugate Candidates
22/12/2021 21:11
Dec 22 (Reuters) - Adagene Inc 978y.F :
* ADAGENE ACHIEVES KEY MILESTONE IN COLLABORATION WITH
EXELIXIS
FOR SAFEBODY® NOVEL MASKED ANTIBODY-DRUG CONJUGATE CANDIDATES
* ADAGENE INC - WILL RECEIVE A $3 MILLION MILESTONE PAYMENT
FOR
SUCCESSFUL NOMINATION OF LEAD SAFEBODY CANDIDATES FOR ONE OF ITS
COLLABORATION PROGRAMS
Source text for Eikon: ID:nGNX7vdtld
Further company coverage: 978y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adagene
See all newsBrief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate